SynCardia and Hydrix Enter into Development Collaboration to Advance the Emperor, SynCardia's Next Generation Total Artificial Heart

Impact · against what's priced in

The collaboration to develop the 'Emperor' total artificial heart provides a positive catalyst for both companies, particularly for Picard Medical via potential Australian R&D tax credits. While the development is multi-year and phased, it validates Hydrix's engineering capabilities and advances Picard's transition toward a fully implantable device.

PMI+0.50

No priced-in read yet